Immutep and MSD Partner for Phase III NSCLC Trial

Immutep (ASX: IMM) announced a collaboration with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA (pembrolizumab) and chemotherapy in a Phase III trial for first-line treatment of metastatic non-small cell lung cancer (NSCLC). The TACTI-004 trial will enroll around 750 patients regardless of PD-L1 expression to address the entire NSCLC market eligible for anti-PD-1 therapy. Immutep will lead the trial, while MSD will supply KEYTRUDA.

The combination of efti and KEYTRUDA has shown promising efficacy and safety in treating NSCLC across all PD-L1 expression levels. The trial aims to improve clinical outcomes and expand the number of responders in the NSCLC patient population. The study will be randomized, double-blind, and controlled, with dual primary endpoints of progression-free and overall survival.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com